Show simple item record

dc.contributor.authorMoyle, Peter M
dc.contributor.authorDai, Wei
dc.contributor.authorLiu, Tzu-Yu
dc.contributor.authorHussein, Waleed M
dc.contributor.authorMaruthayanar, Pirashanthini
dc.contributor.authorWells, James W
dc.contributor.authorMcMillan, Nigel AJ
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorToth, Istvan
dc.date.accessioned2018-11-16T01:39:15Z
dc.date.available2018-11-16T01:39:15Z
dc.date.issued2015
dc.identifier.issn0960-894X
dc.identifier.doi10.1016/j.bmcl.2015.10.049
dc.identifier.urihttp://hdl.handle.net/10072/101900
dc.description.abstractHuman papillomaviruses (HPVs) are associated with various cancers, with HPV16 linked to more than half of cervical cancer cases. Vaccines to prevent HPV infection and cancer development have proven effective, but are not useful in individuals with prior HPV exposure. Treatment vaccines to eradicate or control HPV-associated lesions are therefore desirable for these patients. Herein we describe the development of a process to enable the production of semisynthetic vaccines based on the site-specific attachment of synthetic bacterial lipid analogs (e.g., Pam2Cys) to a non-oncogenic mutant HPV16 E7 protein to generate molecularly defined vaccines. Many cytotoxic lymphocyte (CTL) epitopes from E7 are delivered by this approach; potentially ensuring that large numbers of immunized individuals can generate CTLs to clear HPV infected cells. Delivery of this construct reduced the growth of HPV16-associated tumors in a TC1 mouse model, the effects of which were better than the potent CTL epitope HPV16 E7(44–57) administered with Montanide ISA51 adjuvant.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom5570
dc.relation.ispartofpageto5575
dc.relation.ispartofissue23
dc.relation.ispartofjournalBioorganic & Medicinal Chemistry Letters
dc.relation.ispartofvolume25
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry not elsewhere classified
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry
dc.subject.fieldofresearchOrganic Chemistry
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode030499
dc.subject.fieldofresearchcode0304
dc.subject.fieldofresearchcode0305
dc.subject.fieldofresearchcode1115
dc.titleCombined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2015 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorMcMillan, Nigel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record